HE4联合CA125检测在早期卵巢癌诊断中的价值

摘要
图/表
参考文献(15)
相关文章 (1)

全文: PDF (0 KB) HTML (27 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究人附睾分泌蛋白4（HE4）联合糖类抗原 125（CA125）检测在诊断早期卵巢癌中的价值。方法选择2015年6月～2017年3月在我院诊断治疗的50例卵巢癌患者、40例盆腔良性肿物患者及健康体检者50例，分别检测三组入选者的血HE4、CA125浓度，比较两项指标在卵巢癌诊断中的价值。结果卵巢癌组患者血清HE4浓度显著高于盆腔良性肿物组，差异有统计学意义（P＜0.05）。盆腔良性肿物组患者血清HE4浓度与对照组比较，差异无统计学意义（P＞0.05）。卵巢癌组患者血清CA125浓度显著高于盆腔良性肿物组，差异有统计学意义（P＜0.05）；盆腔良性肿物组患者血清CA125浓度显著高于对照组，差异有统计学意义（P＜0.05），HE4组在卵巢癌的灵敏度为 88.00%（44/50）、特异度为 93.48%（86/92），高于 CA125 组的 60.00%（30/50）、79.59%（78/98），差异有统计学意义（P＜0.05），HE4 组与 CA125 组比较，差异无统计学意义（Z=1.395、P=0.164），HE4 与 HE4 联合 CA125 比较，差异无统计学意义（Z=0.705、P=0.481），CA125组同HE4联合CA125组比较，差异有统计学意义（Z=2.723、P=0.0062）。结论HE4联合CA125检测在诊断早期卵巢癌中的价值优于单独检测HE4及CA125，能作为临床卵巢癌诊断的无创方法之一。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王胤人
	闫凯

关键词 ：卵巢癌, 人附睾分泌蛋白4, 糖类抗原 125, 诊断价值

Abstract：ObjectiveTo investigate the value of human epididymal secretory protein 4 (HE4)combined with carbohydrate antigen 125 (CA125)in the diagnosis of early ovarian cancer.MethodsFrom June 2015 to March 2017,50 patients with ovarian cancer,40 patients with pelvic benign tumor,and 50 healthy subjects for physical examinations were selected.The blood HE4 and CA125 concentrations of the three groups were detected.The value of two indicators in the diagnosis of ovarian cancer was compared.ResultsSerum HE4 concentration in ovarian cancer group was significantly higher than that in pelvic benign tumor group(P＜0.05).There was no significant difference in serum HE4 concentration between pelvic benign tumor group and control group (P＞0.05).Serum CA125 concentration in ovarian cancer group was significantly higher than that in pelvic benign tumor group (P＜0.05).The serum CA125 concentration of patients with pelvic benign tumor group was significantly higher than that of the control group.The difference was statistically significant(P＜0.05).The sensitivity and specificity of HE4 group in ovarian cancer were 88.00%(44/50)and 93.48%(86/92),which was higher than that of CA125 group of 60.00%(30/50)and 79.59%(78/98),the difference was statistically significant(P＜0.05).There was no statistically significant difference between HE4 group and CA125 group(Z=1.395,P=0.164).There was no statistically significant difference between HE4 and HE4 combined CA125 group(Z=0.705,P=0.481).There was statistically significant difference between CA125 group and HE4 combined CA125 group(Z=2.723,P=0.0062).ConclusionThe value of HE4 combined with CA125 in the diagnosis of early ovarian cancer is better than that of HE4 or CA125 alone.It can be considered as one of the noninvasive methods for the diagnosis of ovarian cancer.

Key words： Ovarian cancer Epididymal secretory protein 4 Carbohydrate antigen 125 Diagnostic value

引用本文:

王胤人;闫凯. HE4联合CA125检测在早期卵巢癌诊断中的价值[J]. 中国当代医药, 2018, 25(6): 114-116.
WANG Yin-ren;YAN Kai. Diagnostic value of HE4 combined with CA125 detection in early ovarian cancer. 中国当代医药, 2018, 25(6): 114-116.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I6/114

[1]	吕晓梅，陈涛，张小强，等.血清 HE4，CA125，CA199，CA724联合检测对卵巢癌早期诊断的临床价值探讨[J].国际检验医学杂志，2016，38（9）：83.
[2]	Amal Z，Azzam·Doaa I，Hashad·Nahla A，et al.Evaluation of HE4 as an extrabiomarker to improve detection of ovarian carcinoma：is it time for a step forward?[J].Arch Gynecol Obstet，2013，288（1）：167-172.
[3]	高磊，刘晓霞，王泳心，等.血清糖类抗原125和人附睾蛋白4联合检测在卵巢癌诊断中的价值[J].中国老年学杂志，2016，36（12）：2958-2959.
[4]	Siegel R，Naishadham D，Jemal A.Cancer statistics，2012[J].CA Cancer J Clin，2012，62（1）：10-29.
[5]	孙洁.CA199、CA125及HE4在卵巢癌中的检测意义[J].中国实验诊断学，2016，20（7）：91-93.
[6]	龚红霞，徐明娟.联合检测 HE4、CA125、CA19-9 和 CEA在卵巢癌诊断中的应用[J].中国医学前沿杂志（电子版），2015，7（10）：41-44.
[7]	Karlsen MA，Hogdall EVS，Christensen IJ，et al.A novel diagnostic index combining HE4，CA125 and age may improve triage of women with suspected ovarian cancer-an international multicenter study in women with an ovarian mass[J].Gynecol Oncol，2015，138（3）：640-646.
[8]	唐丽媛，谢力，王晓囡，等.血清 HE4，CA125 和 CA199 检测在卵巢肿瘤诊断中的临床意义[J].中国妇幼保健，2015，30（15）：2352-2353.
[9]	Kondalsamy-Chennakesavan S，Hackethal A，Bowtell D，et al.Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4，CA125，and CEA and patient′s age[J].Gynecol Oncol，2013，129（5）：467-471.
[10]	贾素娟，王治洁，张美琴，等.血清 HE4，CA125 和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值[J].中国癌症杂志，2015，25（6）：452-456.
[11]	Sandri MT，Bottari F，Franchi D，et al.Comparison of HE4，CA125 and ROMA algorithm in women with a pelvic mass：correlation with pathological outcome[J].Gynecol Oncol，2013，128 （2）：233-238.
[12]	朱振宇，魏娜，严妮子.HE4联合CA125在卵巢癌早期诊断中的应用价值[J].现代肿瘤医学，2014，22（3）：623-624.
[13]	郝艳梅，郝亚飞.血清HE4和CA125联检对卵巢癌的诊断价值[J].国际检验医学杂志，2017，38（7）：981-983.
[14]	Romagnolo C，Leon AE，Fabricio ASC，et al.HE4，CA125 andriskofovarianmalignancyalgorithm（ROMA）asdiagnostic tools for ovarian cancer in patients with a pelvic mass：an Italian multicenter study[J].Gynecol Oncol，2016，141（2）：303-311.
[15]	胥琳璟，郑晓霞，王斌，等.血清 HE4、CA125 联合 TVCDS 诊断早期卵巢癌的应用分[J].河北医药，2017，39（5）：668-670.